Target Name: ZBTB33
NCBI ID: G10009
Review Report on ZBTB33 Target / Biomarker Content of Review Report on ZBTB33 Target / Biomarker
Other Name(s): KAISO_HUMAN | Transcriptional regulator Kaiso | ZBTB33 variant 2 | zinc finger and BTB domain containing 33 | Zinc finger and BTB domain containing 33, transcript variant 2 | zinc finger and BTB domain-containing protein 33 | ZNF-kaiso | kaiso transcription factor | Kaiso transcription factor | WUGSC:H_DJ525N14.1 | ZNF348 | Kaiso | KAISO | Zinc finger and BTB domain-containing protein 33 | OTTHUMP00000023935

ZBTB33: A Promising Drug Target and Biomarker for Various Diseases

In recent years, researchers around the world have been exploring the potential of ZBTB33 as both a drug target and a biomarker for various diseases. ZBTB33, a zinc finger and BTB domain-containing protein, has garnered significant attention due to its involvement in several critical cellular processes. This article delves into the significance of ZBTB33 and its potential role in drug development and disease diagnosis.

Understanding ZBTB33:
ZBTB33, also known as Kaiso, is a transcriptional regulator that binds to methylated DNA sequences. It is found in the nucleus of cells, where it plays a crucial role in gene expression and regulation. ZBTB33 is involved in various signaling pathways, including Wnt, Notch, and TGF-尾, making it a central player in numerous cellular processes, including development, differentiation, and cellular response to stimuli.

Role of ZBTB33 as a Drug Target:
The diverse involvement of ZBTB33 in critical cellular pathways makes it an attractive candidate for drug development. By modulating the activity of ZBTB33, researchers seek to manipulate downstream cellular processes and potentially treat a variety of diseases. For instance, in cancer research, targeting ZBTB33 has shown promising results in inhibiting cancer cell proliferation and inducing apoptosis.

ZBTB33 in Cancer:
Cancer, a disease characterized by uncontrolled cell growth, is a major global health concern. Mounting evidence suggests that aberrant regulation of ZBTB33 is involved in the development and progression of various cancers. Research has identified elevated expression of ZBTB33 in several types of cancer, including colorectal, breast, and pancreatic cancers. This upregulation has been associated with poor prognosis and resistance to conventional cancer therapies.

Targeting ZBTB33 for Cancer Treatment:
Given its association with cancer development and progression, ZBTB33 presents an exciting opportunity as a therapeutic target. Researchers are exploring different strategies to modulate the activity of ZBTB33 and develop targeted anti-cancer therapies. One approach involves small molecule inhibitors that disrupt the interaction between ZBTB33 and its DNA-binding partners. These inhibitors have shown promising results in preclinical studies, highlighting the potential of ZBTB33 as a therapeutic target for cancer patients.

ZBTB33 as a Biomarker:
Apart from its therapeutic potential, ZBTB33 also shows promise as a biomarker for various diseases. Biomarkers are measurable substances that indicate the presence or progression of a particular disease. They can aid in early detection, diagnosis, and monitoring of diseases, providing valuable information for personalized treatment strategies.

ZBTB33 as a Diagnostic Biomarker:
In many diseases, including cancer and cardiovascular disorders, ZBTB33 expression levels have been shown to correlate with disease severity and progression. For instance, studies have reported higher levels of ZBTB33 in patients with advanced stages of breast cancer compared to those with early-stage disease. This suggests that ZBTB33 could serve as a diagnostic biomarker, enabling clinicians to identify individuals at higher risk or in need of more aggressive treatment.

ZBTB33 as a Prognostic Biomarker:
Furthermore, ZBTB33 levels have also been found to predict patient outcomes. In lung cancer, for example, high expression levels of ZBTB33 have been associated with poorer prognosis and decreased survival rates. These findings highlight the prognostic value of ZBTB33 as a biomarker, helping clinicians tailor treatment plans and improve patient outcomes.

The Future of ZBTB33:
As research on ZBTB33 continues to progress, its potential as both a drug target and a biomarker becomes increasingly apparent. If further studies confirm its efficacy, ZBTB33-targeted therapies could revolutionize treatment strategies for various diseases, particularly cancer. Additionally, ZBTB33 biomarker assays could provide essential diagnostic and prognostic information, enhancing personalized medicine approaches and improving patient care.

ZBTB33, with its multifaceted role in cellular processes and its potential as both a drug target and a biomarker, represents an exciting avenue of research in the field of medicine. By properly understanding the functions and molecular interactions of ZBTB33, researchers can leverage this knowledge to develop innovative therapies and diagnostic tools. As ongoing studies continue to unveil the intricacies of ZBTB33, we may witness significant advancements in the diagnosis, treatment, and management of various diseases.

Protein Name: Zinc Finger And BTB Domain Containing 33

Functions: Transcriptional regulator with bimodal DNA-binding specificity. Binds to methylated CpG dinucleotides in the consensus sequence 5'-CGCG-3' and also binds to the non-methylated consensus sequence 5'-CTGCNA-3' also known as the consensus kaiso binding site (KBS). Recruits the N-CoR repressor complex to promote histone deacetylation and the formation of repressive chromatin structures in target gene promoters. May contribute to the repression of target genes of the Wnt signaling pathway. May also activate transcription of a subset of target genes by the recruitment of CTNND2. Represses expression of MMP7 in conjunction with transcriptional corepressors CBFA2T3, CBFA2T2 and RUNX1T1 (PubMed:23251453)

The "ZBTB33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

ZBTB42 | ZBTB48 | ZBTB49 | ZCCHC10 | ZCCHC12 | ZDHHC12-DT | ZDHHC13 | ZDHHC20P1 | ZDHHC20P2 | ZEB2-AS1 | ZFAND6 | ZFC3H1 | ZFHX4-AS1 | ZFP1 | ZFPM1 | ZFX-AS1 | ZFYVE1 | ZFYVE27 | ZFYVE9P1 | ZGLP1 | ZHX1-C8orf76 | ZMYM4-AS1 | ZNF100 | ZNF114 | ZNF169 | ZNF197 | ZNF213-AS1 | ZNF225-AS1 | ZNF236-DT | ZNF256 | ZNF263 | ZNF280D | ZNF296 | ZNF316 | ZNF320 | ZNF33BP1 | ZNF350-AS1 | ZNF354B | ZNF354C | ZNF355P | ZNF366 | ZNF367 | ZNF37BP | ZNF383 | ZNF384 | ZNF385D-AS1 | ZNF385D-AS2 | ZNF431 | ZNF433 | ZNF467 | ZNF48 | ZNF488 | ZNF497 | ZNF503-AS2 | ZNF511 | ZNF519 | ZNF519P3 | ZNF525 | ZNF540 | ZNF550 | ZNF559-ZNF177 | ZNF562 | ZNF564 | ZNF567 | ZNF571-AS1 | ZNF579 | ZNF585A | ZNF586 | ZNF587B | ZNF594-DT | ZNF596 | ZNF600 | ZNF605 | ZNF610 | ZNF625-ZNF20 | ZNF626 | ZNF627 | ZNF663P | ZNF664-RFLNA | ZNF667-AS1 | ZNF670-ZNF695 | ZNF675 | ZNF676 | ZNF679 | ZNF705B | ZNF705EP | ZNF705G | ZNF709 | ZNF717 | ZNF721 | ZNF729 | ZNF730 | ZNF737 | ZNF778 | ZNF780B | ZNF781 | ZNF783 | ZNF791 | ZNF800 | ZNF807P